European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo

▴ European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo
“The EMA’s decision to validate our application represents important progress for the esophageal cancer community, and we look forward to potentially bringing Opdivo to patients in the EU who may benefit.”

Bristol Myers Squibb today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients with residual pathologic disease after neoadjuvant chemoradiotherapy (CRT) and resection. Validation of the application confirms that submission is complete, and the EMA’s centralized review process will begin.

The application is based on results from the Phase 3 CheckMate -577 trial, in which Opdivo doubled median disease-free survival (DFS) - its primary endpoint – in patients with esophageal or GEJ cancer, following neoadjuvant CRT and tumor resection. The safety profile of Opdivo as adjuvant therapy in the CheckMate -577 trial was consistent with that reported in previous Opdivo studies.

“The majority of esophageal cancer patients with localized disease who are treated with both chemotherapy and surgery do not achieve complete response. Their risk of recurrence is unacceptably high and the establishment of more effective treatment options is essential,” said Ian M. Waxman, M.D., development lead, gastrointestinal cancers, Bristol Myers Squibb. “The EMA’s decision to validate our application represents important progress for the esophageal cancer community, and we look forward to potentially bringing Opdivo to patients in the EU who may benefit.”

Bristol Myers Squibb thanks the patients and investigators who have been involved in the CheckMate -577 trial.

Tags : #LatestPharmaNewsJan5 #LatestBristolMyersSquibbNewsJan5 #TreatmentforEsophagealCancer

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Moving Towards Better Mental Health: Know The Impact of Low-intensity Workout For Your Mental Well-being April 29, 2024
Exploring Mortality Risks for Lesbian and Bisexual Women: Key Findings from a Comprehensive Research EffortApril 29, 2024
Implications of Alcohol Intake During Pregnancy on Fetal Development: New Study Reveals Subtle ChangesApril 29, 2024
Indian Air Force's Night Vision Rescue: Soldier’s Life Saved in High-Stakes AirliftApril 29, 2024
Now You Can Also Buy Insurance For Your Parents Aged Above 65 years: IRDAI Lifts Age Cap for Health Insurance Expanding Healthcare AccessApril 29, 2024
Ensuring Infection Control: Central Government Hospitals Implement New Safety MeasuresApril 29, 2024
Dish TV Revolutionizes Entertainment with ‘Dish TV Smart+’ Services, Offering TV and OTT on Any Screen, AnywhereApril 26, 2024
Arohan Financial Services Recognized Among India's Best Workplaces in BFSI 2024April 26, 2024
Why Podcasts Are the Next Big Thing in Healthcare Advertising in IndiaApril 26, 2024
Challenges of Child Growth at High Altitudes: New Study Reveals ImpactApril 26, 2024
Staying Cool in India's Scorching Heat: Heatwave Safety TipsApril 26, 2024
The Dark Side of Neotame (Artificial Sweetener): New Research Raises Concerns about Gut HealthApril 26, 2024
Sightsavers India Fellowship Program Invites Applications for Promising OphthalmologistsApril 25, 2024
Transforming Brain Healthcare: India's Visionary Task Force for Neurological DisordersApril 25, 2024
The Battle Against Malaria: Rising Trends and Vaccine InnovationsApril 25, 2024
Talc and Asbestos Controversy: Inside Johnson & Johnson's Courtroom StruggleApril 25, 2024
The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024